Pulmonary Hypertension Associated with Congenital Heart Disease: A Clinical Primer

被引:0
作者
Landry, Lily M. [1 ]
Jenks, Christopher L. [2 ]
机构
[1] Johns Hopkins All Childrens Hosp, Heart Inst, Dept Pediat, St Petersburg, FL 33701 USA
[2] Univ Oklahoma, Dept Pediat, Div Crit Care, Hlth Sci Ctr, Oklahoma City, OK 73014 USA
关键词
Pulmonary arterial hypertension; congenital heart disease; pulmonary hypertension associated with congenital heart disease; ARTERIAL-HYPERTENSION; VASCULAR-DISEASE; DOUBLE-BLIND; MACITENTAN; EFFICACY; AMBRISENTAN; MANAGEMENT; SELEXIPAG; RIOCIGUAT; DIAGNOSIS;
D O I
10.32604/chd.2025.066142
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Pulmonary hypertension associated with congenital heart disease represents a significant challenge for clinicians due to its complex pathophysiology and diverse presentation. This patient population exhibits a broad spectrum of anatomical and hemodynamic abnormalities, with congenital heart disease-associated pulmonary arterial hypertension (PAH-CHD) comprising a significant proportion of pediatric pulmonary hypertension (PH) cases. Although progress in diagnostic methods and treatment options has been made, PH continues to be a major contributor to illness and death among affected pediatric patients, especially when diagnosis or treatment is postponed. This review aims to equip non-specialist clinicians with a better understanding of PH associated with congenital heart disease, focusing on its pathophysiology, clinical presentation, and diagnostic criteria. Key recommendations for evaluating and managing this fragile population are presented, emphasizing the importance of early recognition and multidisciplinary collaboration. As an increasing number of congenital heart disease patients reach adulthood, understanding its lifelong impacts becomes crucial for improving outcomes and creating tailored treatment approaches.
引用
收藏
页码:325 / 339
页数:15
相关论文
共 75 条
[1]   Characterisation of paediatric pulmonary hypertensive vascular disease from the PPHNet Registry [J].
Abman, Steven H. ;
Mullen, Mary P. ;
Sleeper, Lynn A. ;
Austin, Eric D. ;
Rosenzweig, Erika B. ;
Kinsella, John P. ;
Ivy, Dunbar ;
Hopper, Rachel K. ;
Raj, J. Usha ;
Fineman, Jeffrey ;
Keller, Roberta L. ;
Bates, Angela ;
Krishnan, Usha S. ;
Avitabile, Catherine M. ;
Davidson, Alexander ;
Natter, Marc D. ;
Mandl, Kenneth D. .
EUROPEAN RESPIRATORY JOURNAL, 2022, 59 (01)
[2]   Macitentan in infants and children with pulmonary hypertensive vascular disease. Feasibility, tolerability and practical issues - a single-centre experience [J].
Albinni, Sulaima ;
Pavo, Imre ;
Kitzmueller, Erwin ;
Michel-Behnke, Ina .
PULMONARY CIRCULATION, 2021, 11 (01)
[3]   Efficacy of phosphodiesterase type 5 inhibitors in univentricular congenital heart disease: the SV-INHIBITION study design [J].
Amedro, Pascal ;
Gavotto, Arthur ;
Abassi, Hamouda ;
Picot, Marie-Christine ;
Matecki, Stefan ;
Malekzadeh-Milani, Sophie ;
Levy, Marilyne ;
Ladouceur, Magalie ;
Ovaert, Caroline ;
Aldebert, Philippe ;
Thambo, Jean-Benoit ;
Fraisse, Alain ;
Humbert, Marc ;
Cohen, Sarah ;
Baruteau, Alban-Elouen ;
Karsenty, Clement ;
Bonnet, Damien ;
Hascoet, Sebastien .
ESC HEART FAILURE, 2020, 7 (02) :747-756
[4]   Hemodynamic assessment and acute pulmonary vasoreactivity testing in the evaluation of children with pulmonary vascular disease. Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK [J].
Apitz, Christian ;
Hansmann, Georg ;
Schranz, Dietmar .
HEART, 2016, 102 :23-29
[5]   Echocardiographic assessment of pulmonary hypertension: A guideline protocol from the British Society of Echocardiography [J].
Augustine D.X. ;
Coates-Bradshaw L.D. ;
Willis J. ;
Harkness A. ;
Ring L. ;
Grapsa J. ;
Coghlan G. ;
Kaye N. ;
Oxborough D. ;
Robinson S. ;
Sandoval J. ;
Rana B.S. ;
Siva A. ;
Nihoyannopoulos P. ;
Howard L.S. ;
Fox K. ;
Bhattacharyya S. ;
Sharma V. ;
Steeds R.P. ;
Mathew T. .
Echo Research & Practice, 2018, 5 (3) :G11-G24
[6]   Drug Treatment of Pulmonary Hypertension in Children [J].
Avitabile, Catherine M. ;
Vorhies, Erika E. ;
Ivy, David Dunbar .
PEDIATRIC DRUGS, 2020, 22 (02) :123-147
[7]   Clinical efficacy and safety of switch from bosentan to macitentan in children and young adults with pulmonary arterial hypertension: extended study results [J].
Aypar, Ebru ;
Alehan, Dursun ;
Karagoz, Tevfik ;
Aykan, Hakan ;
Ertugrul, Ilker .
CARDIOLOGY IN THE YOUNG, 2020, 30 (05) :681-685
[8]   Phosphodiesterase 5 inhibitors for pulmonary hypertension [J].
Barnes, Hayley ;
Brown, Zoe ;
Burns, Andrew ;
Williams, Trevor .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2019, (01)
[9]   Survival in Childhood Pulmonary Arterial Hypertension Insights From the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management [J].
Barst, Robyn J. ;
McGoon, Michael D. ;
Elliott, C. Gregory ;
Foreman, Aimee J. ;
Miller, Dave P. ;
Ivy, D. Dunbar .
CIRCULATION, 2012, 125 (01) :113-122
[10]   The association of N-terminal pro-brain-type natriuretic peptide with hemodynamics and functional capacity in therapy-naive precapillary pulmonary hypertension: results from a cohort study [J].
Berghaus, T. M. ;
Kutsch, J. ;
Faul, C. ;
von Scheidt, W. ;
Schwaiblmair, M. .
BMC PULMONARY MEDICINE, 2017, 17